Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …

Ketamine is the first exemplar of a rapid-acting antidepressant with efficacy for treatment-
resistant symptoms of mood disorders. Its discovery emerged from a reconceptualization of …

Ketamine is the prototype for a new generation of glutamate-based antidepressants that
rapidly alleviate depression within hours of treatment. Over the past decade, there has been …

Major depressive disorder (MDD) is a leading cause of suicide in the world. Monoamine-
based antidepressant drugs are a primary line of treatment for this mental disorder, although …

Over the last two decades, the dissociative anaesthetic agent ketamine, an uncompetitive N-
Methyl-D-Aspartate (NMDA) receptor antagonist, has emerged as a novel therapy for …

The discovery of ketamine's rapid and robust antidepressant effects opened a window into a
new generation of antidepressants. Multiple controlled trials and open‐label studies have …

The discovery of the rapid-acting antidepressant effects of ketamine has 1) led to a paradigm
shift in our perception of what is possible in treating severe depression; 2) spurred a wave of …

Major depressive disorder (MDD) is a common and debilitating psychiatric disorder.
Traditional antidepressants are of limited efficacy and take weeks to months to yield full …

Highlights•The recent paradigm shift in drug development due to ketamine is described.•A
historical overview of novel and repurposed antidepressant drugs is provided.•Mechanisms …

Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that
purpose, has garnered marked interest over the past two decades as an emerging treatment …